Background: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) systems are increasingly being available and used for staging examinations. Brain metastases (BM) are frequent in patients with non-small cell lung cancer (NSCLC) and decisive for treatment strategy. Purpose: To assess the diagnostic value of integrated 18F-2-fluoro-2-deoxy-D glucose (18F-FDG) PET/MRI in initial staging in patients with NSCLC for BM in comparison to MRI alone. Material and Methods: Eighty-three patients were prospectively enrolled for an integrated 18F-FDG PET/MRI examination. The 3 T MRI protocol included a fluid-attenuated inversion-recovery sequence (FLAIR) and a contrast-enhanced three-dimensional magnetization prepared rapid acquisition GRE sequence (MPRAGE). Two neuroradiologists evaluated the datasets in consensus regarding: (i) present lesions; (ii) size of lesions; and (iii) number of lesions detected in MRI alone, compared to the PET component when reading the 18F-FDG PET/MRI. Results: Based on MRI alone, BM were detected in 15 out of the 83 patients, comprising a total of 39 metastases. Based on PET alone, six patients out of the 83 patients were rated positive for metastatic disease, revealing a total of 15 metastases. PET detected no additional BM. The size of the BM correlated positively with sensitivity of detection in PET. Conclusion: The sensitivity of PET in detection of BM depends on their size. 18F-FDG PET/MRI does not lead to an improvement in diagnostic accuracy in cerebral staging of NSCLC patients, as MRI alone remains the gold standard.
Introduction
Non-small cell lung cancer (NSCLC) is the most frequent malignant lung cancer with a high percentage of distant metastases in initial staging. The rate of brain metastasis has been reported up to 43% (1, 2) . In general, brain metastases (BM) affect treatment strategy in patients with NSCLC. Therefore, cerebral imaging is advised. The American College of Chest Physicians (ACCP) recommends cerebral staging in patients with stage III or IV lung cancer, whereas recent publications and guidelines advice cerebral staging regardless of preoperative stage and/or in all patients with curative therapeutic options (3) (4) (5) (6) . Solitary BM might be treated either neurosurgically or by gamma knife therapy, potentially leading to higher overall survival (7, 8) . Whole brain radiotherapy is the treatment option of choice in patients with inoperable or multiple metastases smaller than 3 cm (9) .
The concept of combined metabolic and morphologic imaging has been well established in oncology (10) . Initial studies with a subsequent imaging concept of positron emission tomography (PET) and magnetic resonance imaging (MRI) with subsequent fusion reveal a lack of precision for cerebral staging in NSCLC due to misregistration artifacts, originating from the sequential data acquisition (11) . With the introduction of integrated 18F-2-fluoro-2-deoxy-D glucose (18F-FDG) PET/MRI systems, numerous studies showed the high diagnostic competence of this emerging hybrid imaging technique in the evaluation of diverse tumor entities (12, 13) .
Hence, the aim of our study was to evaluate the diagnostic ability of integrated 18F-FDG PET/MRI compared with MRI alone serving as gold standard for cerebral staging of NSCLC patients.
Material and Methods Patients
The present study was conducted in accordance with all guidelines set forth by the approving institutional review board. Eighty-three consecutive patients (30 women, 53 men; mean age, 61.5 years; age range, 41-85 years) with histologically proven NSCLC were enrolled in this trial. All patients were assigned for an initial cerebral staging with 18F-FDG PET/MRI. The cerebral imaging was part of a whole-body staging with initial 18F-FDG PET/CT and subsequent whole-body 18F-FDG PET/MRI.
Reference standard
Histopathological confirmation of NSCLC was available in all patients. Diagnosis of brain metastasis was made on a consensus interpretation based on morphological assessment in MRI (T1-hypointense lesion with hemorrhagic or non-hemorrhagic appearance, uniform or ring-enhancing pattern, T2-hyperintense peritumoral edema). In addition, all available prior examinations and cross-sectional imaging-follow up (MRI, computed tomography [CT]) were used for the determination of brain metastasis. Due to ethical reasons brain metastasis diagnosed by MRI were not routinely confirmed by biopsy. Patients without lesions in MRI and PET were considered free of brain metastases. Patients with ambiguous lesions in MRI were followed up my MRI after 3 months.
PET/MRI
18F-FDG PET/MRI was performed on an integrated 3 T hybrid PET/MRI system (Biograph mMR, Siemens Healthcare GmbH, Erlangen, Germany). All patients first underwent routine PET/CT of thorax and abdomen (60 min after intravenous injection of a bodyweight-adapted dose of 18F-FDG (290 AE 40 MBq). Thereafter, PET/MRI started with a delay of 148 AE 28 min after tracer injection. Patients were bedded headfirst supine and imaging from the head to the upper thighs was performed in caudo-cranial direction. A dedicated 16-channel head and neck radiofrequency (RF) product coil was used for MRI. MRI was performed simultaneously to PET data acquisition. The MRI protocol included a fluid-attenuated inversionrecovery sequence (FLAIR) sequence (FLAIR: slice thickness, 6 mm; TR, 9000 ms; TE, 94 ms; matrix, 256 Â 192; flip angle [FA,], 150 ; inversion time, 900 ms) and a contrast-enhanced three-dimensional magnetization-prepared rapid-acquisition GRE sequence (ceMPRAGE) acquired in sagittal plane and reformatted in axial and coronal orientation (MPRAGE: slice thickness, 1 mm; TR, 1820 ms; TE, 3.15 ms; matrix, 512 Â 256; FA, 9 ; inversion time, 900 ms). The contrast-enhanced sequence was obtained 20 min after bolus injection of a dose of 0.2 mL/kg paramagnetic contrast agent with a flow rate of 2 mL/s (Dotarem Õ , Guerbet, Sulzbach/Taunus, Germany) (single dose).
Image interpretation
All datasets were analyzed using dedicated viewing software for hybrid imaging (OsiriX, Pixmeo SARL, Bernex, Switzerland). Two neuroradiologists analyzed the images in consensus in random order. Both readers were blinded to the patients' identification data and the stage of the disease. Image analysis was performed in two steps: (i) MRI sequences; and (ii) integrated 18F-FDG PET/MRI datasets with a time interval of 4 weeks between the two ratings to avoid recognition bias. For each modality, image rating comprised: (i) presence of BM (yes, no); (ii) size of BM (mm); and (iii) number of BM (n).
Statistical analysis
Data are presented both based on patient and lesion. Descriptive analysis was performed to present the results of the ratings of MRI and PET for the identification of cerebral metastases. Furthermore, the sensitivity of PET for the detection of metastases in dependence of lesions size was calculated.
Results

Patient-based analysis
Based on the reference standard, metastases were present in 15 out of 83 patients. Consequently, MRI alone identified metastases in all 15 patients (100%) ( Table 1) .
Among the remaining 68 patients without cerebral metastatic spread, 67 (98.5 %) were correctly identified, while in one patient MRI was rated false positive.
Furthermore, based on the PET data, 6/15 patients (40%) with cerebral metastases were correctly identified (Figs 1 and 2) , while in the remaining nine patients, metastatic disease was missed ( Fig. 3 ). PET did not show any focal tracer accumulation, suspicious of cerebral metastases, in the 68 patients without cerebral tumor spread.
Lesion-based analysis
A total of 39 lesions were depicted and classified as malignant according to the reference standard.
All 39 lesions were visible on MRI (100%). Based on the PET component of hybrid 18F-FDG PET/MRI datasets 15/39 metastases showed a metabolic correlate (38.5%), whereas the remaining 24 metastases were only visible on MRI (61.5%). Moreover, PET did not detect any additional metastases.
On MRI one lesion was rated as false positive. In that case, a single, small cortical lesion was misinterpreted as a metastasis (Fig. 4 ) but was finally identified as a small venous vessel based on further follow-up imaging.
Among the 39 metastases that were depicted, 13 had a maximum diameter of less than 5 mm; in 15 cases the maximum diameter was in the range of 5-10 mm and the remaining 11 metastases were larger than 10 mm. Detectability of metastases in dependence of lesions size in PET is illustrated in Table 2 .
Based on MRI alone 13 metastases smaller than 5 mm were detected. Based on the PET-component of hybrid 18F-FDG PET/MRI, 1/13 was correctly identified as a metastasis (8% sensitivity < 5 mm). Considering the size range of 5-10 mm, 15 metastases were detected on MRI and three in PET (27% sensitivity). A total of 11 metastases larger than 10 mm were described in MRI with a pathologic correlate in the PET-component in nine patients (82% sensitivity). PET did not detect any additional metastases.
Discussion
In our study, we investigated the diagnostic value of integrated 18F-FDG PET/MRI in initial staging in patients with NSCLC for brain metastasis in comparison to MRI alone. MRI detected all BM (100%). Based on PET alone, only 6/15 patients (40%) were rated positive for metastatic disease, revealing a total of 15 metastases. In this study 18F-FDG PET detected no additional BM. The size of the BM correlated positively with sensitivity of detection in 18F-FDG. The presence of BM determines treatment strategies in patients with NSCLC, underlining the importance of high quality imaging. Especially in patients in good neurological condition at the time of diagnosis, early detection of BM can lead to an improvement in survival (14, 15) . The incidence of BM in our study population amounted to 18.1%, which is comparable to previous studies describing a range of incidence of 12.6-21.1% in NSCLC patients with initial staging (11, 16) . While a higher incidence of cerebral metastases has been described in symptomatic patients compared to asymptomatic patients (11, 17, 18) , current studies recommend cerebral staging at initial diagnosis of lung cancer, regardless of the neurological status (3). In numerous studies, MRI was described to provide higher sensitivity for the diagnosis of BM in patients with lung cancer than CT or PET/CT (11, 19) . Whereas in whole-body staging, many studies and a metaanalysis of 8699 patients demonstrated significant higher sensitivity and specificity of PET/CT in patients with NSCLC compared to contrast-enhanced CT or PET alone (20) .
After the introduction of integrated PET/MR systems, this emerging hybrid imaging technique has been in focus of scientific research within the last years. Numerous studies demonstrated the feasibility as well as its excellent diagnostic potential in various applications of oncologic imaging. While most studies revealed its diagnostic equivalence to PET/CT for whole-body staging, e.g. in lung cancer (12) , the exchange of the morphological imaging modality from CT to MRI enables a new platform for MRbased imaging regions, such as the brain. Hence, the aim of this study was to evaluate a potential benefit of the combined analysis of metabolic and morphologic features for assessment of BM.
The increasing availability of integrated 18F-FDG PET/MRI systems offers the possibility of a one-stop-shop staging modality providing useful morphologic and metabolic information. Especially when imaging intracranial structures, MRI is the modality of choice providing an excellent morphological contrast. In combining the morphological information with the metabolic status simultaneous 18F-FDG PET/MRI evoked the expectation of an improvement of cerebral staging. Moreover, integrated 18F-FDG PET/MRI systems offer a time-saving in the staging procedure when different examinations can be combined. One result of the present study is that 18F-FDG PET/MRI does not improve diagnostic accuracy in cerebral staging of NSCLC patients compared to MRI alone. Advantages of integrated 18F-FDG PET/ MRI like simultaneous multi-modal data acquisition cannot overcome the general limitations of MRI and PET-only systems like the limited spatial resolution of PET (21) . The PET component of integrated 18F-FDG PET/MRI protocols may even lead to uncertainty in diagnosis due to the relative high number of falsenegative findings as in the present study. The sensitivity of PET correlates to the size of metastases. Therefore, PET misses smaller BM. Especially for small lesions (<5 mm diameter) cerebral 18F-FDG PET/MRI shows its weakness by detecting only 8% of metastases in our study population. Small metastases are missed when using unspecific radionuclides like 18F-FDG in a surrounding with a high basal metabolic rate like the brain. Moreover, 18F-FDG PET does not even reliably detect larger BM. Nevertheless, whole-body staging with integrated PET/MRI seems to be an attractive one-stop-shop staging modality, which saves examination time and contrast agent. However, it is important to be aware of the diagnostic lack of the 18F-FDG PET component in brain metastases staging and to rely decisively on MRI in this application. Sensitivity of 18F-FDG PET in detection of BM strictly depends on their size. In future, more selective tracers for BM might help to improve sensitivity of PET. As research in the area advances, and the field of molecular imaging gets wider, this may become feasible in the future.
MRI is more sensitive in cerebral staging of BM, which might also be explained by the physiologic 18F-FDG uptake of the brain. BM are fogged by the high background noise of the cerebral glucose metabolism and consequently missed. Moreover, it might be possible that glucose metabolism of metastases does not exceed the level of glucose metabolism of the brain, making the metabolic imaging concept for cerebral metastases useless. This is different in tumors without blood-brain barrier disruption, like primary brain tumors, where metabolic imaging can improve diagnostic accuracy. MRI, in contrast, is highly sensitive in cerebral staging for BM, because of the high spatial resolution of MRI (22) . Metastases are normally not separated from the circulation by the blood-brain barrier and therefore accumulate contrast agent, detectable by MRI. The cerebral enhancement is therefore not necessarily a sign of hyper vascularization compared to other tissues. The limitations of our study were as follows. First, BM were not histopathologically confirmed. However, pathological confirmation of BM is usually not indicated and was therefore not performed in this study. Second, a single dose contrast agent was used in this study due to the whole-body staging protocol. A dedicated cerebral MR-protocol with a T1-TSE-sequence and double dose of contrast agent would improve even sensitivity and specificity of MRI (23, 24) .
In conclusion, integrated 18F-FDG PET/MRI does not lead to an improvement in diagnostic accuracy in cerebral staging of NSCLC patients, as MRI alone remains to be the gold standard.
